Mutation screening of beta-defensin 2 promoter in Crohn's disease patients of Guangdong area

YC Zhang,FZ Zhi,JH Long,CQ Zhong,L Chen,J He,YY Zhang
DOI: https://doi.org/10.3321/j.issn:1673-8225.2007.39.017
2007-01-01
Abstract:AIM:To screen the mutation of promoter in human β-defensin 2 (HBD-2) of Crohn’s disease patients and control subjects in Guangdong province, so as to investigate the role of HBD-2 gene in the pathogenesis of Crohn's disease. METHODS: The experiment was conducted in the Department of Gastroenterology, Nanfang Hospital of Southern Medical University between January 2002 and October 2006. And 5 mL blood samples were obtained from 45 patients with Crohn's disease and 50 healthy controls. They all knew and agreed to the therapy scheme and signed informed consent. DNA was extracted from the blood samples. And the DNA fragments of promoter in HBD-2 were acquired by PCR amplification and primer sequence. Whereas distilled water was adopted for negative control. We ensured the success of the PCR production through purification, and DNA sequencing was carried out by the company of invitrogen. DNAMAN software was used to compare the patient's sequence of HBD-2 gene with normal control's, as well as gene bank data (http://www.ncbi.nlm.nih.gov/BLAST/). The software of SPSS 13.0 was used for statistics analysis about the relationship of gene mutation with the characteristics of Crohn's disease. RESULTS: ①All the forty-five Crohn's disease patients and 50 health controls entered the analysis of results, there was no statistical significance in sex and age.②Four Crohn's disease patients were found HBD-2 mutation located at promoter -233(G→C) and codon from AGG to AGC. Amino acid turned from Arginine to Serine among 45 patients, and there was significant difference compared with healthy control (χ2=4.34, P < 0.05).④The lesion of four patients who had HBD-2 mutation was all located in small bowel (χ2=10.81, P < 0.01) and the disease was serious. CONCLUSION: Some patients with Crohn's disease carry mutation of promoter in HBD-2, the mutations is related to the age of patients onset, the location of lesion and the severity of disease, so we need further study to identify the function of the mutation.
What problem does this paper attempt to address?